GET DAILY SIGNALSOrthoPediatrics (KIDS) Shares Climb +23% in 30 Days After Strong Q3 Results
Key Takeaways
- KIDS shares climbed roughly 23% over the last 30 days, from a closing level near $22.58 to approximately $27.75, driven largely by a strong third-quarter report.
- Third-quarter 2026 revenue rose 19% year over year to a record $72.7 million, and management raised full-year revenue guidance to $270–$273 million.
- Adjusted EBITDA reached a record $6.9 million, while free cash flow turned positive at $1.6 million, reinforcing an improving profitability story.
- The FDA cleared the PNP Femur Retrograde Nail System, and the company completed its first implantations, extending its pediatric nailing platform.
- Analyst sentiment improved, with Piper Sandler raising its price target to $30 from $25 while maintaining an Overweight rating.
- Insider selling remains a point of caution for investors, even as institutional ownership stays elevated.
- For additional detail on analyst expectations, explore our pages for Price Targets, Earnings, and Forecast.
- Explore Trending AI Robots to see how automated trading strategies are approaching KIDS and thousands of other tickers.
OrthoPediatrics (KIDS) Business Focus and Competitive Position
OrthoPediatrics Corp. (KIDS) is a medical device company devoted exclusively to pediatric orthopedics. Founded in 2006 and headquartered in Warsaw, Indiana, the company designs, develops, and markets anatomically appropriate implants, instruments, and braces for children with orthopedic conditions, including trauma, deformity, and scoliosis. It distributes roughly 80 surgical and specialized bracing systems through a dedicated sales force across the United States and a growing international footprint.
The company's so-called innovation "super cycle" has become central to its growth narrative, with recent launches such as the 3P Hip plating system, the Traxeo and VerteGlide systems, and an expanding pediatric nailing portfolio. Its OrthoPediatrics Specialty Bracing (OPSB) franchise, which has grown to more than 60 clinics and 34 systems, targets non-surgical treatment, broadening the addressable market. From what I see, investors follow KIDS for its niche leadership in an underserved segment, its double-digit revenue growth, and its progress toward sustained profitability and free cash flow. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
KIDS Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, KIDS advanced roughly 23%, from a closing price near $22.58 to approximately $27.75. Most of that move was concentrated in the period immediately following the company's third-quarter earnings release on October 27, 2026, which triggered a sharp intraday rally that carried shares to fresh multi-year highs.
The quarterly trend is even stronger. Over the last three months, the stock has risen approximately 40%, from a level near $19.84 in late July to its current price. The shares began a sustained upward trend in early August and have since broken above prior trading ranges. In short, the 30-day gain represents an acceleration of a multi-month uptrend rather than an isolated event.
Key Drivers Behind the Recent 30-Day Move in KIDS
The primary catalyst was the company's third-quarter 2026 results. OrthoPediatrics reported record revenue of $72.7 million, up 19% from $61.2 million a year earlier and above analyst consensus estimates. U.S. revenue rose 19% to $57.9 million, while international revenue increased 18% to $14.8 million, with Trauma & Deformity and Scoliosis both posting strong growth.
Management lifted full-year 2026 revenue guidance to a range of $270 million to $273 million, up from a prior range of $265 million to $269 million, implying 14% to 16% growth. Profitability also improved: adjusted EBITDA reached a record $6.9 million, and free cash flow turned positive at $1.6 million, compared with a $3.4 million outflow in the prior-year quarter.
Additional catalysts reinforced the move. The company announced FDA 510(k) clearance of its PNP Femur Retrograde Nail System and completed its first implantations, expanding its pediatric nailing platform. Analysts responded favorably, with Piper Sandler raising its price target to $30 from $25 and maintaining an Overweight rating. Collectively, these developments improved investor sentiment around the company's growth and margin trajectory.
What Supported the Broader Quarterly Advance in KIDS
The broader quarterly rally began in early August, when second-quarter results beat expectations and sparked a re-rating of the shares. Since then, a series of analyst price-target increases—including moves from Needham and BTIG—has supported the advance, alongside progress on the company's innovation super cycle.
Strategic activity also shaped the multi-month trend. OrthoPediatrics completed acquisitions, including The Spinecorporation Limited in July 2026, aimed at broadening its product portfolio and addressable market. Steady contributions from the OPSB bracing franchise and ramping adoption of new implant systems reinforced the view that the company can sustain double-digit revenue growth while improving operating leverage. The combination of top-line momentum, better profitability, and expanding institutional interest underpinned the stock's roughly 40% gain over the quarter.
Key Factors to Monitor for KIDS Going Forward
Looking ahead, the key factor will be execution against the company's raised full-year guidance and its ability to sustain double-digit revenue growth. Investors should monitor the ramp of new "super cycle" products, including the 3P plating platform and the pediatric nailing systems, as these move from limited to full commercial launches.
Profitability metrics will remain in focus, particularly the company's stated goal of reaching positive free cash flow in 2027 and continued expansion of adjusted EBITDA. The growth of the OPSB bracing clinics and international market penetration are additional demand drivers to track. On the risk side, elevated sales and marketing spending, ongoing insider selling, and broader macroeconomic factors affecting hospital procedure volumes and med-tech valuations could influence sentiment. These considerations, rather than near-term price swings, are likely to shape the stock's longer-term direction. I’m watching this closely as the company moves into 2027.
Exploring AI Tools in My Research Workflow
In my day-to-day analysis, I turn to Tickeron’s AI Trend Prediction Engine to cross-check momentum signals and pattern formations across healthcare names like this one. It helps me quickly gauge how automated models are interpreting the same data points I review manually, adding another layer of perspective without replacing fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KIDS's RSI Indicator leaves overbought zone
The 10-day RSI Oscillator for KIDS moved out of overbought territory on October 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In 20 of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KIDS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
KIDS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on KIDS as a result. In 57 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for KIDS just turned positive on October 20, 2026. Looking at past instances where KIDS's MACD turned positive, the stock continued to rise in 27 of 40 cases over the following month. The odds of a continued upward trend are 68%.
KIDS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KIDS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 72%.
Following a +5.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where KIDS advanced for three days, in 217 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.810) is normal, around the industry mean (3.837). P/E Ratio (-14.179) is within average values for comparable stocks, (2.078). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.175) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. KIDS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KIDS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of orthopedic devices
Industry MedicalNursingServices
Advertisement